Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Chromatrap® Enriches Epigenetic Marks from Primary Cells

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
New application note from Porvair Sciences.

A new application note from Porvair Sciences details a protocol for its Chromatrap® ChIP assay kit that has been developed to enrich epigenetic marks from primary human tissue cells.

Chromatrap® Pro-A, the novel solid-based matrix for chromatin immunoprecipitation assays (ChIP) has been successfully used for isolation of high quality chromatin from difficult biopsy material.

Focusing on an application to precipitate epigenetic marks from primary endometrial stromal cells - results show high abundant epigenetic marks from 1 million cells isolated from a tissue biopsy, with selective amplification of positive gene targets relative to negative IgG and negative gene loci.

Not only is Chromatrap proven to produce positive amplification of histone regulatory marks at specific gene loci but also the novel ChIP assay kit is shown to be compatible with human tissue.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Porvair Filtration Group Receives Queen’s Award for Enterprise in International Trade
This award had been made in recognition of Porvair’s substantial growth in overseas business, achieving increased year-on-year growth in sales of exported products over the past three years.
Tuesday, April 21, 2015
Biomedical Researcher wins Microplate Catalogue Prize Draw
A scientist at the Genomics CoreLab of the NIHR Biomedical Research Centre at Addenbrooke's Hospital (Cambridge, UK) has won Porvair Sciences' latest free prize draw for people registering online for the company's 2010-2011 Microplate Catalogue.
Wednesday, January 26, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!